Clinical Trials
51 trialsAn Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
LUPARPED
Fundación de investigación HM
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
University of Colorado, Denver
TAPUR
American Society of Clinical Oncology
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
University of California, San Francisco
RAINBO
Leiden University Medical Center
I-SPY
QuantumLeap Healthcare Collaborative
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
PROOV
The Netherlands Cancer Institute
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Memorial Sloan Kettering Cancer Center
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
Surgical Pembro +/- Olaparib w TMZ for rGBM
Dana-Farber Cancer Institute
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Pembro With Radiation With or Without Olaparib
University of Kentucky
NePtune
Hoosier Cancer Research Network
RAINBO-RED
Gustave Roussy, Cancer Campus, Grand Paris
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
SOLARA
Hoosier Cancer Research Network
CONCORDE
University of Leeds
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
Fondazione Ricerca Traslazionale
ELEMENT
GBG Forschungs GmbH
PHOEBE
Dartmouth-Hitchcock Medical Center
NeoADAPT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Cambridge University Hospitals NHS Foundation Trust
ROYAL
Azienda Ospedaliero-Universitaria di Modena
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Dana-Farber Cancer Institute
PHOENIX
Institute of Cancer Research, United Kingdom
MOST plus
Centre Leon Berard
THOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
PRRT-PARPi
Erasmus Medical Center
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Post-CDK
Seoul National University Hospital
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
COROS
Santa Chiara Hospital
OPTIMUM
Asan Medical Center
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
SOLID
University Health Network, Toronto
PROACTIVE
Radboud University Medical Center
PALBOLA
Azienda Ospedaliero-Universitaria di Modena
ICARUSBREAST02
Gustave Roussy, Cancer Campus, Grand Paris
DRUP
The Netherlands Cancer Institute
MITO 35B
National Cancer Institute, Naples